144 related articles for article (PubMed ID: 19276142)
21. A study evaluating the efficacy and tolerability of tropisetron in combination with dexamethasone in the prevention of delayed platinum-induced nausea and emesis.
Sorbe BG; Berglind AM; Andersson H; Boman K; Högberg T; Hallgren M; Schmidt M
Cancer; 1998 Sep; 83(5):1022-32. PubMed ID: 9731907
[TBL] [Abstract][Full Text] [Related]
22. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
Sorbe BG
Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
[TBL] [Abstract][Full Text] [Related]
23. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
24. [Effectiveness of Steroid Rotation in a Japanese Patient with Hiccups Caused by Dexamethasone: a Case Report].
Hosokawa H; Shimoda H; Ishii T
Yakugaku Zasshi; 2019; 139(4):647-650. PubMed ID: 30930401
[TBL] [Abstract][Full Text] [Related]
25. Aprepitant as salvage therapy in patients with chemotherapy-induced nausea and emesis refractory to prophylaxis with 5-HT(3) antagonists and dexamethasone.
Oechsle K; Müller MR; Hartmann JT; Kanz L; Bokemeyer C
Onkologie; 2006 Dec; 29(12):557-61. PubMed ID: 17202825
[TBL] [Abstract][Full Text] [Related]
26. A retrospective review of antiemetic use for chemotherapy-induced nausea and vomiting in pediatric oncology patients at a tertiary care center.
Aseeri M; Mukhtar A; Al Khansa S; Elimam N; Jastaniah W
J Oncol Pharm Pract; 2013 Jun; 19(2):138-44. PubMed ID: 23034405
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support.
Paul B; Trovato JA; Thompson J; Badros AZ; Goloubeva O
J Oncol Pharm Pract; 2010 Mar; 16(1):45-51. PubMed ID: 19525301
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Warr DG; Hesketh PJ; Gralla RJ; Muss HB; Herrstedt J; Eisenberg PD; Raftopoulos H; Grunberg SM; Gabriel M; Rodgers A; Bohidar N; Klinger G; Hustad CM; Horgan KJ; Skobieranda F
J Clin Oncol; 2005 Apr; 23(12):2822-30. PubMed ID: 15837996
[TBL] [Abstract][Full Text] [Related]
29. [Report of a case effectively treated by appropriate therapy for severe anticipatory nausea and vomiting due to FOLFOX or FOLFIRI].
Mori M; Kiba T; Oikawa M; Hokkoku K; Watanabe Y; Nakagawa T; Shintaku K; Yoshimitsu Y; Sakuma H; Ueda H; Nakai M
Gan To Kagaku Ryoho; 2009 Feb; 36(2):325-7. PubMed ID: 19223757
[TBL] [Abstract][Full Text] [Related]
30. A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer.
Chen ML; Fang CH; Liang LS; Dai LH; Wang XK
Surg Oncol; 2010 Mar; 19(1):38-45. PubMed ID: 19345093
[TBL] [Abstract][Full Text] [Related]
31. Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study.
Llombart-Cussac A; Ramos M; Dalmau E; García-Saenz JA; González-Farré X; Murillo L; Calvo L; Morales S; Carañana V; González A; Fernández-Morales LA; Moreno F; Casas MI; Angulo Mdel M; Cámara MC; Garcia-Mace AI; Carrasco E; Jara-Sánchez C
Eur J Cancer; 2016 May; 58():122-9. PubMed ID: 26994459
[TBL] [Abstract][Full Text] [Related]
32. Anaphylactic reaction to oxaliplatin: a case report.
Larzillière I; Brandissou S; Breton P; Lingoungou A; Gargot D; Ramain JP; Harnois C
Am J Gastroenterol; 1999 Nov; 94(11):3387-8. PubMed ID: 10566767
[No Abstract] [Full Text] [Related]
33. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community.
Hickok JT; Roscoe JA; Morrow GR; King DK; Atkins JN; Fitch TR
Cancer; 2003 Jun; 97(11):2880-6. PubMed ID: 12767103
[TBL] [Abstract][Full Text] [Related]
34. Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy.
Vardy J; Chiew KS; Galica J; Pond GR; Tannock IF
Br J Cancer; 2006 Apr; 94(7):1011-5. PubMed ID: 16552437
[TBL] [Abstract][Full Text] [Related]
35. Comparative activity of antiemetic drugs.
Jordan K; Schmoll HJ; Aapro MS
Crit Rev Oncol Hematol; 2007 Feb; 61(2):162-75. PubMed ID: 17208005
[TBL] [Abstract][Full Text] [Related]
36. [A search for the risk factors for hiccups and evaluation of antiemetic therapy in CDDP-based chemotherapy, using cluster analysis].
Asano H; Watanabe M; Kawaguchi A; Yanae M; Funakami Y; Wada T; Matzno S; Yamazoe Y; Nishida S; Ichida S
Gan To Kagaku Ryoho; 2013 Aug; 40(8):1031-6. PubMed ID: 23986046
[TBL] [Abstract][Full Text] [Related]
37. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
Gebbia V; Majello E; Testa A; Pezzella G; Giuseppe S; Giotta F; Riccardi F; Fortunato S; Colucci G; Gebbia N
Cancer; 1996 Sep; 78(6):1300-7. PubMed ID: 8826954
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of a continuous infusion, patient controlled anti-emetic pump to facilitate outpatient administration of high-dose chemotherapy.
Dix S; Cord M; Howard S; Coon J; Belt R; Geller R
Bone Marrow Transplant; 1999 Sep; 24(5):561-6. PubMed ID: 10482943
[TBL] [Abstract][Full Text] [Related]
39. [A case of stage IV AFP producing cecal cancer responding to mFOLFOX6 leading to a partial response].
Seshimo K; Yamashita Y; Oishi M; Yokomichi N; Ikeda H; Katoh H; Yamamura M; Kodera M; Maejima R; Kobayashi K; Takita K
Gan To Kagaku Ryoho; 2009 Aug; 36(8):1375-7. PubMed ID: 19692783
[TBL] [Abstract][Full Text] [Related]
40. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
